Scholarlink

Purpose <p>To evaluate the real-world efficacy and safety of adalimumab (ADA) combined with conventional therapy in patients with chronic non-infectious anterior uveitis (NIAU).</p> Methods <p>This retrospective cohort study included 114 patients with chronic NIAU treated at a single tertiary center between May 2022 and May 2025. Patients were divided into a study group receiving ADA plus conventional therapy (n = 58) and a control group receiving conventional therapy alone (n = 56). Anterior chamber (AC) cell count, best-corrected visual acuity (BCVA), treatment response, adjunctive therapy use, complications and adverse events were compared over 6&#xa0;months. Multivariate logistic regression was performed to identify factors associated with complete remission.</p> Results <p>At 3 and 6&#xa0;months, the ADA group showed significantly lower AC cell counts and greater BCVA improvement than controls (all P &lt; 0.05). At 6&#xa0;months, complete remission was achieved in 84.5% of the ADA group versus 64.3% of controls, with lower relapse rates (13.8% vs. 28.6%, both P &lt; 0.05). After adjustment, ADA use was independently associated with complete remission (adjusted OR = 2.85, 95% CI 1.15–7.05). The ADA group required less adjunctive corticosteroid and immunosuppressive therapy and had lower rates of cataract and ocular hypertension. Most adverse events were mild, with one serious infection leading to discontinuation.</p> Conclusion <p>In real-world practice, adalimumab combined with conventional therapy is associated with improved inflammation control, visual outcomes and reduced relapse in chronic NIAU, with an acceptable safety profile.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of adalimumab in chronic non-infectious anterior uveitis: a retrospective study

  • 期刊论文

  • 发表日期：

    2026年3月12日

查看全文
  • Guopeng Ding,
  • Guijun Xie,
  • Guolong Ding,
  • Shu Lei

摘要

Purpose

To evaluate the real-world efficacy and safety of adalimumab (ADA) combined with conventional therapy in patients with chronic non-infectious anterior uveitis (NIAU).

Methods

This retrospective cohort study included 114 patients with chronic NIAU treated at a single tertiary center between May 2022 and May 2025. Patients were divided into a study group receiving ADA plus conventional therapy (n = 58) and a control group receiving conventional therapy alone (n = 56). Anterior chamber (AC) cell count, best-corrected visual acuity (BCVA), treatment response, adjunctive therapy use, complications and adverse events were compared over 6 months. Multivariate logistic regression was performed to identify factors associated with complete remission.

Results

At 3 and 6 months, the ADA group showed significantly lower AC cell counts and greater BCVA improvement than controls (all P < 0.05). At 6 months, complete remission was achieved in 84.5% of the ADA group versus 64.3% of controls, with lower relapse rates (13.8% vs. 28.6%, both P < 0.05). After adjustment, ADA use was independently associated with complete remission (adjusted OR = 2.85, 95% CI 1.15–7.05). The ADA group required less adjunctive corticosteroid and immunosuppressive therapy and had lower rates of cataract and ocular hypertension. Most adverse events were mild, with one serious infection leading to discontinuation.

Conclusion

In real-world practice, adalimumab combined with conventional therapy is associated with improved inflammation control, visual outcomes and reduced relapse in chronic NIAU, with an acceptable safety profile.